Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00003776

Trial Description

start of 1:1-Block title

Title

Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Due to progressive therapy intensification in the four consecutive studies AML-BFM 78, 83,
93 and 98, prognosis for children with acute myeloid leukemia (AML) has improved steadily.
In spite of the intensified therapy, rates of morbidity and mortality have remained
unchanged or have even decreased. Against the background that about 40% of the patients
still die from immediate causes of an underlying disease relapse or of nonresponse, it seems
to be justifiable to intensify therapy - especially for high-risk patients - which on its
parts will require an optimization of supportive measures. As the present risk
stratification into standard- (SR) and high-risk (HR) patients has proved effective, we will
pursue the risk-adapted therapy strategy.

The aim of the study is to improve prognosis in children with AML by intensification of
cytostatic therapy and to evaluate by randomisation the equivalence of a prophylactic
central nervous system (CNS) irradiation with a total dose of 18 Gy versus 12 Gy.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

During the last decade, prognosis in acute myelogenous leukemia (AML) in childhood has
improved considerably, but still 30% of the children experience a relapse of disease and
further 10% fail to respond sufficiently to the present therapies. A further intensification
of therapy might improve the overall survival of these children, but possible, implicit side
effects have to be considered carefully. Increase in dose intensification of the proven,
effective anthracyclines will be limited by the risk of cumulative cardiotoxicity. A
liposomal formulation of daunorubicin may offer a possibility to increase dosage, at least
partially, without causing cumulative cardiotoxicity. Objective one of this randomised study
is to ascertain if this dose increase improves therapy response and overall survival at
acceptable toxicity. The previous experiences with liposomal daunorubicin, gathered from the
relapse studies AML-BFM Rez 97 and International Therapy Study Relapsed AML 2001/012 as well
as from the pilot study AML-BFM 2002P, have shown that the induction therapy is feasible in
clinical centers with experience in AML therapy without leading to a marked increase of
toxicity or prolongation of granulocytopenia.

First results of study AML-BFM 98 have shown that the patients of the standard risk (SR)
group did not benefit from an additional, second induction (HAM). On this account we did not
reintroduce this second induction course in the present study AML-BFM 2004. However, SR
patients will take part in the randomisation of initial therapy with a general view to
achieving higher effectiveness.

For patients of the high-risk group, the administration of 2-chloro-2-deoxyadenosine (2-CDA)
will be integrated in the first phase of consolidation to achieve an even higher
intensification. It could be shown that 2-CDA possesses good antileukemic activity in
pediatric and adult AML. In a phase-II study it could also be demonstrated that 2-CDA has
good effectiveness in combination with cytarabine. Results of phase-II studies conducted at
St. Jude Children's Hospital, Memphis, showed that 2-CDA has good effectiveness especially
in children with monoblastic leukemias (FAB M4/M5). Consequently, this intensification for
high-risk patients, who present in more than half of the cases with monoblastic leukemias
(FAB M4/5), may allow further improvement of therapy for this cohort. The pilot study
AML-BFM 2002P confirmed that the study design was practicable without increasing
significantly the risk of higher toxicity. However, median duration of aplasia was
significantly prolonged in comparison to that of the AI (cytarabine, idarubicin)-block.
Objective two of this study is to determine by randomisation if an improvement of efficiency
is possible.

Study AML-BFM 98 has already focussed on the question of whether or not doses of CNS
irradiation of 12 Gy and 18 Gy are equivalent with regard to their capacity of reducing the
risk of relapse. As the results of study AML-BFM 87 confirmed the necessity of CNS
irradiation, but did not reveal the necessary minimum dose, this randomisation has been
implemented in order to prevent, as far as possible, late sequelae of CNS irradiation by
reducing the radiation dose (= objective three).

As the number of patients of study AML-BFM 98 was not sufficient to resolve this question,
this randomised analysis has been extended for a second period and will therefore be
continued in the current study AML-BFM-2004.

Besides the intensification of cytostatic therapy, study AML-BFM 2004 seeks to optimise the
quality of supportive therapy by implementing measures of quality assurance. This demands an
up-to-date, complete documentation of each therapy phase. In studies AML-BFM 93 and 98,
about 12% of deaths were due to primary complications such as leukostasis syndrome,
haemorrhage or severe infections (4%), infections in aplasia before achieving remission (4%)
or infections in remission (4%). Maybe the lives of even more children will be saved in the
future by improved standards for the prevention of primary complications. Further, the
efficacy of chemotherapy could be improved by less delays in therapy which are often due to
infections or other complications.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003776
  •   2012/05/03
  •   2005/05/19
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00111345  (ClinicalTrials.gov)
  •   BfArM 4022064  (University Hospital Muenster)
  •   DKH 50-2728 
  •   4022064 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Myeloid Leukemia
  •   C92.0 -  Acute myeloid leukaemia
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Anthracyclines
  •   Drug: liposomal daunorubicin
  •   Drug: 2-CDA
  •   Drug: AI
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   II-III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2; time frame: 5 years
- Concerning objective 3: Disease-free survival from the date of randomisation; time frame: 5 years

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Cardiotoxicity; time frame: 5 years

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2004/03/31
  •   550
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   18   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Age from >0 to </=18 years

- De novo AML, including children with Down syndrome, primary myelosarcomas or acute
mixed lineage leukemia/biphenotypic leukemia (predominantly myeloid)

- Admission to one of the member hospitals in Germany participating in the study
AML-BFM 2004

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Children with pre-existing syndromes (except Down syndrome)

- AML as secondary malignancy

- Accompanying diseases which do not allow therapy according to the protocol

- Pre-treatment for more than 14 days with another intensive induction therapy

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • University Hospital Muenster
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Deutsche Krebshilfe e.V., Bonn (Germany)
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Medical School Hannover
    • Ursula Creutzig, Prof. Dr. med. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Medical School Hannover
    • Ursula Creutzig, Prof. Dr. med. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   8
  •   2013/10/30
* This entry means the parameter is not applicable or has not been set.